case_images: PMC6339711_01
case_images: Immunohistochemical analysis of the breast lesion. (a) H&E 200x: central necrosis is observed, peripheral neoplastic cells with eosinophilic cytoplasm, large nuclei, prominent nucleoli, atypical mitosis, and mononuclear infiltrates. Representative micrographs (at 400x) are shown for immunohistochemical analysis of (b) leukocyte common antigen (LCA), showing positive expression in peritumoral lymphocytes. (c) Ki67 expression is detected in 60% of cancer cells; lack of expression of (d) estrogen receptor (ER), (e) progesterone receptor (PR), and (f) HER2.
case_images: CRIONM2019-6958952.001.jpg
case_images: PMC6339711_01_CRIONM2019-6958952.001.jpg
case_images: fig1
case_images: Pathology and immunohistochemistry of the lesion (60 x 40 mm) revealed an estrogen receptor negative (ER-), progesterone receptor negative (PR-), HER2 negative (HER2-), and Ki67 index of 20% mass (Figure 1), which led to the diagnosis of adenocarcinoma stage IIB (pT3N0M0) of the right breast.
case_images: BRCA2 pathogenic variant: c.3606_3607del (p.Ser1203Cysfs).
case_images: CRIONM2019-6958952.002.jpg
case_images: PMC6339711_01_CRIONM2019-6958952.002.jpg
case_images: fig2
case_images: Genetic testing for BRCA1 or BRCA2 mutations (Myriad Genetics) reported a BRCA2 deleterious mutation: c.3606_3607del (p.Ser1203Cysfs) (Figure 2).